Sarepta Therapeutics,, Inc. Common Stock
Here’s whether Sarepta Therapeutics,, Inc. Common Stock (SRPT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.86% over 10 days); RSI 59 — healthy momentum range. Concerns: weak 1-year return of -60.0%; declining volume on rally — weak conviction (0.71x 30d avg). Currently 66.7% off its 52-week high. Score: +3/7.
SRPT is in a confirmed uptrend, trading above both its 50-day ($18.97) and 200-day ($19.59) moving averages. An RSI of 58.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -60.0% compares to +35.1% for SPY (trailed the market by 95.1%). The current 66.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.